Statistical review of Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial

The following review has been prepared in collaboration with members of the MRC-NIHR Trials Methodology Research Partnership 1. The reviewers named above, and other, unnamed discussants of the paper, are all qualified statisticians with experience in clinical  rials. Our objective is to provide a rapid review of publications, preprints and protocols from clinical trials of COVID-19  treatments, independent of journal specific review processes. We aim to provide timely, constructive, focused, clear advice aimed at  improving both the research outputs under review, as well as future studies. Given our collective expertise (clinical trial statistics) our  eviews focus on the designs of the trials and other statistical content (methods, presentation and accuracy of results,  inferences). This review reflects the expert opinions of the named authors, and does not imply endorsement by the MRC-NIHR Trials  Methodology Research Partnership, its wider membership, or any other organization.

Here we review Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial, by Li et al. A pre-proof version of the accepted, peer-reviewed manuscript was published by Med (Cell  ress) https://marlin-prod.literatumonline.com/pb-assets/products/coronavirus/MEDJ1.pdf, following posting of a preprint on  medRxiv on April 15th, 2020: https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v2.